Hydrogenation process for the formation of 3,5-dihydro HMG-CoA reductase inhibitors
US4826999A · kind A · utility
0Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 1987 |
| Grant date | May 2, 1989 |
| Priority date | — |
| Expiry date | Sep 3, 2007 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F7/1804
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel hydrogenation process, using a homogenous iridium or rhodium catalyst for selectively adding hydrogen to the 3,5 positions in the polyhydronaphthyl ring of lovastatin, simvastatin or C-8-acyl or C-6-substituted analogs thereof, is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.